{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:32:34Z","timestamp":1786991554166,"version":"build-2736575974"},"reference-count":79,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Biotechnology"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1016\/j.jbiotec.2016.01.018","type":"journal-article","created":{"date-parts":[[2016,1,19]],"date-time":"2016-01-19T15:05:48Z","timestamp":1453215948000},"page":"13-24","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["Improvement of in vitro stability and pharmacokinetics of hIFN-\u03b1 by fusing the carboxyl-terminal peptide of hCG \u03b2-subunit"],"prefix":"10.1016","volume":"221","author":[{"given":"Natalia","family":"Ceaglio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agustina","family":"Gugliotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Bel\u00e9n","family":"Tardivo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dianela","family":"Cravero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Etcheverrigaray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Kratje","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos","family":"Oggero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Pt. 2","key":"10.1016\/j.jbiotec.2016.01.018_bib0005","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1042\/bj2760511","article-title":"Natural human interferon-alpha 2 is O-glycosylated","volume":"276","author":"Adolf","year":"1991","journal-title":"Biochem. J."},{"key":"10.1016\/j.jbiotec.2016.01.018_bib0010","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1007\/s00216-014-8439-7","article-title":"From individual proteins to proteomic samples: characterization of O-glycosylation sites in human chorionic gonadotropin and human-plasma proteins","volume":"407","author":"Bai","year":"2015","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.jbiotec.2016.01.018_bib0015","first-page":"87","article-title":"Pegylated interferons","volume":"1","author":"Baker","year":"2001","journal-title":"Rev. Gastroenterol. Disord."},{"key":"10.1016\/j.jbiotec.2016.01.018_bib0020","doi-asserted-by":"crossref","first-page":"5386","DOI":"10.1016\/S0021-9258(19)63360-0","article-title":"Isolation and amino acid sequence of COOH-terminal fragments from the beta subunit of human choriogonadotropin","volume":"252","author":"Birken","year":"1977","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jbiotec.2016.01.018_bib0025","first-page":"233","article-title":"Distribution of human recombinant interferon-alpha 2 in rat plasma, liver, and experimental liver metastases","volume":"2","author":"Bocci","year":"1990","journal-title":"Mol. Biother."},{"key":"10.1016\/j.jbiotec.2016.01.018_bib0030","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1038\/nrd2422","article-title":"Interferons at age 50: past, current and future impact on biomedicine","volume":"6","author":"Borden","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jbiotec.2016.01.018_bib0035","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1002\/jps.21684","article-title":"Increasing the sialylation of therapeutic glycoproteins: the potential of the sialic acid biosynthetic pathway","volume":"98","author":"Bork","year":"2009","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jbiotec.2016.01.018_bib0040","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.biologicals.2003.12.002","article-title":"Human serum inactivates non-glycosylated but not glycosylated granulocyte colony stimulating factor by a protease dependent mechanism: significance of carbohydrates on the glycosylated molecule","volume":"32","author":"Carter","year":"2004","journal-title":"Biologicals"},{"key":"10.1016\/j.jbiotec.2016.01.018_bib0045","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jbiotec.2009.12.020","article-title":"Highly glycosylated human alpha interferon: an insight into a new therapeutic candidate","volume":"146","author":"Ceaglio","year":"2010","journal-title":"J. Biotechnol."},{"key":"10.1016\/j.jbiotec.2016.01.018_bib0050","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.biochi.2010.04.004","article-title":"Influence of carbohydrates on the stability and structure of a hyperglycosylated human interferon alpha mutein","volume":"92","author":"Ceaglio","year":"2010","journal-title":"Biochimie"},{"key":"10.1016\/j.jbiotec.2016.01.018_bib0055","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.biochi.2007.10.013","article-title":"Novel long-lasting interferon alpha derivatives designed by glycoengineering","volume":"90","author":"Ceaglio","year":"2008","journal-title":"Biochimie"},{"key":"10.1016\/j.jbiotec.2016.01.018_bib0060","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1002\/jps.23229","article-title":"A novel long-acting human growth hormone fusion protein (VRS-317): enhanced in vivo potency and half-life","volume":"101","author":"Cleland","year":"2012","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jbiotec.2016.01.018_bib0065","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.placenta.2010.06.005","article-title":"Hyperglycosylated hCG, a review","volume":"31","author":"Cole","year":"2010","journal-title":"Placenta"},{"key":"10.1016\/j.jbiotec.2016.01.018_bib0070","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.mce.2006.03.047","article-title":"Hyperglycosylated hCG: a variant with separate biological functions to regular hCG","volume":"260\u2013262","author":"Cole","year":"2007","journal-title":"Mol. Cell Endocrinol."},{"key":"10.1016\/j.jbiotec.2016.01.018_bib0075","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ijpharm.2005.12.023","article-title":"G-CSF loaded biodegradable PLGA nanoparticles prepared by a single oil-in-water emulsion method","volume":"311","author":"Choi","year":"2006","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jbiotec.2016.01.018_bib0080","doi-asserted-by":"crossref","first-page":"20053","DOI":"10.1074\/jbc.R700006200","article-title":"Type I interferon receptors: biochemistry and biological functions","volume":"282","author":"de Weerd","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jbiotec.2016.01.018_bib0085","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jim.2008.02.003","article-title":"A scFv antibody fragment as a therapeutic candidate to neutralize a broad diversity of human IFN-alpha subtypes","volume":"334","author":"Depetris","year":"2008","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.jbiotec.2016.01.018_bib0090","doi-asserted-by":"crossref","first-page":"8463","DOI":"10.1128\/JVI.72.11.8463-8471.1998","article-title":"A third-generation lentivirus vector with a conditional packaging system","volume":"72","author":"Dull","year":"1998","journal-title":"J. Virol."},{"key":"10.1016\/j.jbiotec.2016.01.018_bib0095","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.copbio.2009.10.008","article-title":"Expression systems for therapeutic glycoprotein production","volume":"20","author":"Durocher","year":"2009","journal-title":"Curr. Opin. Biotechnol."},{"key":"10.1016\/j.jbiotec.2016.01.018_bib0100","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/S0301-472X(03)00006-7","article-title":"Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin","volume":"31","author":"Egrie","year":"2003","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.jbiotec.2016.01.018_bib0105","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1080\/10826068.2014.907175","article-title":"Therapeutic alpha-interferons protein: structure, production, and biosimilar","volume":"45","author":"El-Baky","year":"2015","journal-title":"Prep. Biochem. Biotechnol."},{"key":"10.1016\/j.jbiotec.2016.01.018_bib0110","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/nbt799","article-title":"Enhancement of therapeutic protein in vivo activities through glycoengineering","volume":"21","author":"Elliott","year":"2003","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jbiotec.2016.01.018_bib0115","unstructured":"EMA\/65507\/2013, rev 1. BEMFOLA. Assessment report. European Medicine Agency. Committee for Medicinal Products for Human Use (CHMP), EMEA, 2013. [Cited June 2014], available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/002615\/WC500166820.pdf."},{"key":"10.1016\/j.jbiotec.2016.01.018_bib0120","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/0076-6879(81)78146-1","article-title":"A convenient and rapid cytopathic effect inhibition assay for interferon","volume":"78","author":"Familletti","year":"1981","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.jbiotec.2016.01.018_bib0125","doi-asserted-by":"crossref","first-page":"5081","DOI":"10.1210\/en.2007-0026","article-title":"Development of a long-acting erythropoietin by fusing the carboxyl-terminal peptide of human chorionic gonadotropin beta-subunit to the coding sequence of human erythropoietin","volume":"148","author":"Fares","year":"2007","journal-title":"Endocrinology"},{"key":"10.1016\/j.jbiotec.2016.01.018_bib0130","doi-asserted-by":"crossref","first-page":"4410","DOI":"10.1210\/en.2009-1431","article-title":"Designing a long-acting human growth hormone (hGH) by fusing the carboxyl-terminal peptide of human chorionic gonadotropin beta-subunit to the coding sequence of hGH","volume":"151","author":"Fares","year":"2010","journal-title":"Endocrinology"},{"key":"10.1016\/j.jbiotec.2016.01.018_bib0135","first-page":"275063","article-title":"Designing a long acting erythropoietin by fusing three carboxyl-terminal peptides of human chorionic gonadotropin beta subunit to the N-terminal and C-terminal coding sequence","volume":"2011","author":"Fares","year":"2011","journal-title":"Int. J. Cell Bio."},{"key":"10.1016\/j.jbiotec.2016.01.018_bib0140","doi-asserted-by":"crossref","first-page":"4304","DOI":"10.1073\/pnas.89.10.4304","article-title":"Design of a long-acting follitropin agonist by fusing the C-terminal sequence of the chorionic gonadotropin beta subunit to the follitropin beta subunit","volume":"89","author":"Fares","year":"1992","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jbiotec.2016.01.018_bib0145","first-page":"54","article-title":"Fusing the carboxy-terminal peptide of the chorionic gonadotropin (CG) beta-subunit to the common alpha-subunit: retention of O-linked glycosylation and enhanced in vivo bioactivity of chimeric human CG","volume":"9","author":"Furuhashi","year":"1995","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.jbiotec.2016.01.018_bib0150","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1038\/nbt.1651","article-title":"Implications of the presence of N-glycolylneuraminic acid in recombinant therapeutic glycoproteins","volume":"28","author":"Ghaderi","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jbiotec.2016.01.018_bib0155","doi-asserted-by":"crossref","first-page":"147","DOI":"10.5661\/bger-28-147","article-title":"Production platforms for biotherapeutic glycoproteins occurrence, impact, and challenges of non-human sialylation","volume":"28","author":"Ghaderi","year":"2012","journal-title":"Biotechnol. Genet. Eng. Rev."},{"key":"10.1016\/j.jbiotec.2016.01.018_bib0160","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1098\/rspb.1957.0048","article-title":"Virus interference. I. The interferon","volume":"147","author":"Isaacs","year":"1957","journal-title":"Proc. R. Soc. Lond. B Biol. Sci."},{"key":"10.1016\/j.jbiotec.2016.01.018_bib0165","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.jmb.2006.11.053","article-title":"Differential receptor subunit affinities of type I interferons govern differential signal activation","volume":"366","author":"Jaks","year":"2007","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.jbiotec.2016.01.018_bib0170","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1742-4658.2009.07429.x","article-title":"Mucin-type O-glycosylation\u2014putting the pieces together","volume":"277","author":"Jensen","year":"2010","journal-title":"FEBS J."},{"key":"10.1016\/j.jbiotec.2016.01.018_bib0175","doi-asserted-by":"crossref","first-page":"3839","DOI":"10.1210\/endo.136.9.7544273","article-title":"Recombinant thyrotropin containing a beta-subunit chimera with the human chorionic gonadotropin-beta carboxy-terminus is biologically active, with a prolonged plasma half-life: role of carbohydrate in bioactivity and metabolic clearance","volume":"136","author":"Joshi","year":"1995","journal-title":"Endocrinology"},{"key":"10.1016\/j.jbiotec.2016.01.018_bib0180","doi-asserted-by":"crossref","first-page":"11602","DOI":"10.1074\/jbc.M610115200","article-title":"An interferon alpha2 mutant optimized by phage display for IFNAR1 binding confers specifically enhanced antitumor activities","volume":"282","author":"Kalie","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jbiotec.2016.01.018_bib0185","doi-asserted-by":"crossref","first-page":"32925","DOI":"10.1074\/jbc.M806019200","article-title":"The stability of the ternary interferon-receptor complex rather than the affinity to the individual subunits dictates differential biological activities","volume":"283","author":"Kalie","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jbiotec.2016.01.018_bib0190","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.bbrc.2004.01.153","article-title":"Glycosylation of onconase increases its conformational stability and toxicity for cancer cells","volume":"315","author":"Kim","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.jbiotec.2016.01.018_bib0195","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1093\/humrep\/deg024","article-title":"Development and characterization of a long-acting recombinant hFSH agonist","volume":"18","author":"Klein","year":"2003","journal-title":"Hum. Reprod."},{"key":"10.1016\/j.jbiotec.2016.01.018_bib0200","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1093\/glycob\/cwu089","article-title":"Probing polypeptide GalNAc-transferase isoform substrate specificities by in vitro analysis","volume":"25","author":"Kong","year":"2015","journal-title":"Glycobiology"},{"key":"10.1016\/j.jbiotec.2016.01.018_bib0205","first-page":"345","article-title":"Human type I interferons: structure and function","volume":"38","author":"Kontsek","year":"1994","journal-title":"Acta Virol."},{"key":"10.1016\/j.jbiotec.2016.01.018_bib0210","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.tibtech.2003.09.002","article-title":"Sugar coating extends half-lives and improves effectiveness of cytokine hormones","volume":"21","author":"Koury","year":"2003","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.jbiotec.2016.01.018_bib0215","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ab.2012.01.002","article-title":"Suppression of peeling during the release of O-glycans by hydrazinolysis","volume":"423","author":"Kozak","year":"2012","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.jbiotec.2016.01.018_bib0220","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/nrd2399","article-title":"Protein therapeutics: a summary and pharmacological classification","volume":"7","author":"Leader","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jbiotec.2016.01.018_bib0225","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.bbrc.2005.11.034","article-title":"The prolonged half-lives of new erythropoietin derivatives via peptide addition","volume":"339","author":"Lee","year":"2006","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.jbiotec.2016.01.018_bib0230","unstructured":"Leung, M.-Y., Cardenas, G.A., Almeida, I.C., Gerken, T.A., 2014 Isoform Specific O-Glycosylation Prediction (ISOGlyP) Version 1.2., p. Available at http:\/\/isoglyp.utep.edu (accessed 31.10.14.)."},{"key":"10.1016\/j.jbiotec.2016.01.018_bib0235","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.cytogfr.2014.07.015","article-title":"Interferons: success in anti-viral immunotherapy","volume":"25","author":"Lin","year":"2014","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.jbiotec.2016.01.018_bib0240","doi-asserted-by":"crossref","first-page":"331","DOI":"10.2165\/00003088-200544040-00001","article-title":"Pharmacokinetic and pharmacodynamic considerations in the development of therapeutic proteins","volume":"44","author":"Mahmood","year":"2005","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jbiotec.2016.01.018_bib0245","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1093\/protein\/14.10.791","article-title":"Increased proteolytic resistance of ribonuclease A by protein engineering","volume":"14","author":"Markert","year":"2001","journal-title":"Protein Eng."},{"key":"10.1016\/j.jbiotec.2016.01.018_bib0250","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/S1359-6446(03)02610-2","article-title":"Rational design and engineering of therapeutic proteins","volume":"8","author":"Marshall","year":"2003","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jbiotec.2016.01.018_bib0255","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1210\/endo-126-1-376","article-title":"The biological role of the carboxyl-terminal extension of human chorionic gonadotropin [corrected] beta-subunit","volume":"126","author":"Matzuk","year":"1990","journal-title":"Endocrinology"},{"key":"10.1016\/j.jbiotec.2016.01.018_bib0260","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1016\/S0021-9258(19)76994-4","article-title":"The role of sialic acid in determining the survival of glycoproteins in the circulation","volume":"246","author":"Morell","year":"1971","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jbiotec.2016.01.018_bib0265","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1126\/science.272.5259.263","article-title":"In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector","volume":"272","author":"Naldini","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.jbiotec.2016.01.018_bib0270","doi-asserted-by":"crossref","first-page":"23022","DOI":"10.1016\/S0021-9258(18)54457-4","article-title":"The effect of carbohydrate on the structure and stability of erythropoietin","volume":"266","author":"Narhi","year":"1991","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jbiotec.2016.01.018_bib0275","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/1045-1056(90)90066-9","article-title":"An in vitro bioassay for quantitation of human interferons by measurements of antiproliferative activity on a continuous human lymphoma cell line","volume":"18","author":"Nederman","year":"1990","journal-title":"Biologicals"},{"key":"10.1016\/j.jbiotec.2016.01.018_bib0280","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1093\/oxfordjournals.jbchem.a124721","article-title":"Immunogenicity of N-glycolylneuraminic acid-containing carbohydrate chains of recombinant human erythropoietin expressed in Chinese hamster ovary cells","volume":"117","author":"Noguchi","year":"1995","journal-title":"J. Biochem."},{"key":"10.1016\/j.jbiotec.2016.01.018_bib0285","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3181\/00379727-178-42024","article-title":"Inactivation of interferon by serum and synovial fluids","volume":"178","author":"O'Kelly","year":"1985","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"10.1016\/j.jbiotec.2016.01.018_bib0290","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.gene.2015.04.087","article-title":"IFNA2: the prototypic human alpha interferon","volume":"567","author":"Paul","year":"2015","journal-title":"Gene"},{"issue":"Suppl. 1","key":"10.1016\/j.jbiotec.2016.01.018_bib0295","first-page":"19","article-title":"Pegylation of interferon alfa: structural and pharmacokinetic properties","volume":"23","author":"Pedder","year":"2003","journal-title":"Semin. Liver Dis."},{"key":"10.1016\/j.jbiotec.2016.01.018_bib0300","doi-asserted-by":"crossref","first-page":"4897","DOI":"10.1021\/jm0497693","article-title":"Reversible PEGylation: a novel technology to release native interferon alpha2 over a prolonged time period","volume":"47","author":"Peleg-Shulman","year":"2004","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jbiotec.2016.01.018_bib0305","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/nmeth.1701","article-title":"SignalP 4.0: discriminating signal peptides from transmembrane regions","volume":"8","author":"Petersen","year":"2011","journal-title":"Nat. Methods"},{"key":"10.1016\/j.jbiotec.2016.01.018_bib0310","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1146\/annurev.bi.50.070181.002341","article-title":"Glycoprotein hormones: structure and function","volume":"50","author":"Pierce","year":"1981","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.jbiotec.2016.01.018_bib0315","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1021\/bc500523t","article-title":"Conjugation of PolyPEG to interferon alpha extends serum half-life while maintaining low viscosity of the conjugate","volume":"26","author":"Podobnik","year":"2015","journal-title":"Bioconjugate Chem."},{"key":"10.1016\/j.jbiotec.2016.01.018_bib0320","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S0169-409X(02)00022-4","article-title":"Chemistry for peptide and protein PEGylation","volume":"54","author":"Roberts","year":"2002","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jbiotec.2016.01.018_bib0325","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1006\/abio.2002.5619","article-title":"An analytical and structural database provides a strategy for sequencing O-glycans from microgram quantities of glycoproteins","volume":"304","author":"Royle","year":"2002","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.jbiotec.2016.01.018_bib0330","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/10409239709085144","article-title":"Glycosylation: heterogeneity and the 3D structure of proteins","volume":"32","author":"Rudd","year":"1997","journal-title":"Crit. Rev. Biochem. Mol. Biol."},{"key":"10.1016\/j.jbiotec.2016.01.018_bib0335","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jmgm.2014.12.001","article-title":"Rational design of hyper-glycosylated interferon beta analogs: a computational strategy for glycoengineering","volume":"56","author":"Samoudi","year":"2015","journal-title":"J. Mol. Graph Model"},{"key":"10.1016\/j.jbiotec.2016.01.018_bib0340","series-title":"Applied Biopharmaceutics & Pharmacokinetics","author":"Shargel","year":"2005"},{"key":"10.1016\/j.jbiotec.2016.01.018_bib0345","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1002\/jps.20319","article-title":"Glycoengineering: the effect of glycosylation on the properties of therapeutic proteins","volume":"94","author":"Sinclair","year":"2005","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jbiotec.2016.01.018_bib0350","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s11096-005-1319-7","article-title":"Side effects of interferon-alpha therapy","volume":"27","author":"Sleijfer","year":"2005","journal-title":"Pharm. World Sci."},{"key":"10.1016\/j.jbiotec.2016.01.018_bib0355","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2165\/11530550-000000000-00000","article-title":"Glycosylation of therapeutic proteins: an effective strategy to optimize efficacy","volume":"24","author":"Sola","year":"2010","journal-title":"BioDrugs"},{"key":"10.1016\/j.jbiotec.2016.01.018_bib0360","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1038\/emboj.2013.79","article-title":"Precision mapping of the human O-GalNAc glycoproteome through SimpleCell technology","volume":"32","author":"Steentoft","year":"2013","journal-title":"EMBO J."},{"key":"10.1016\/j.jbiotec.2016.01.018_bib0365","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1038\/nbt1364","article-title":"Albinterferon alpha-2b: a genetic fusion protein for the treatment of chronic hepatitis C","volume":"25","author":"Subramanian","year":"2007","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jbiotec.2016.01.018_bib0370","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.cell.2011.06.048","article-title":"Structural linkage between ligand discrimination and receptor activation by type I interferons","volume":"146","author":"Thomas","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.jbiotec.2016.01.018_bib0375","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.cytogfr.2014.10.006","article-title":"High efficiency targeting of IFN-alpha activity: possible applications in fighting tumours and infections","volume":"26","author":"Uze","year":"2015","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.jbiotec.2016.01.018_bib0380","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1080\/10409239891204198","article-title":"Concepts and principles of O-linked glycosylation","volume":"33","author":"Van den Steen","year":"1998","journal-title":"Crit. Rev. Biochem. Mol. Biol."},{"key":"10.1016\/j.jbiotec.2016.01.018_bib0385","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0378-5173(99)00152-0","article-title":"Instability, stabilization, and formulation of liquid protein pharmaceuticals","volume":"185","author":"Wang","year":"1999","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jbiotec.2016.01.018_bib0390","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.bbadis.2006.03.009","article-title":"Abnormal glycosylation with hypersialylated O-glycans in patients with Sialuria","volume":"1762","author":"Wopereis","year":"2006","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.jbiotec.2016.01.018_bib0395","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jconrel.2008.03.014","article-title":"Lipidization of human interferon-alpha: a new approach toward improving the delivery of protein drugs","volume":"129","author":"Yuan","year":"2008","journal-title":"J. Control Release"}],"container-title":["Journal of Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168165616300190?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168165616300190?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T19:34:37Z","timestamp":1654112077000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168165616300190"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":79,"alternative-id":["S0168165616300190"],"URL":"https:\/\/doi.org\/10.1016\/j.jbiotec.2016.01.018","relation":{},"ISSN":["0168-1656"],"issn-type":[{"value":"0168-1656","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Improvement of in vitro stability and pharmacokinetics of hIFN-\u03b1 by fusing the carboxyl-terminal peptide of hCG \u03b2-subunit","name":"articletitle","label":"Article Title"},{"value":"Journal of Biotechnology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbiotec.2016.01.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}